Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial

Key Findings:  This study of adjuvant N-palmitoylethanolamide (PEA) for treating negaative symptoms in patients with schizophrenia found that PEA was safe and effective.

Type of Study:  Double Blind Clinical Trial

Study Sample Size:  50

Study Result:  Positive

Study Location(s):  Iran

Year of Pub:  2022

Cannabinoids Studied:  Anandamide (AEA), Palmitoylethanolamide (PEA)

Phytocannabinoid Source:  Not Applicable

Ligands Studied:  Dopamine, Glutamate

Dosage: PEA (600 mg twice a day)

Route of Administration:  Oral (Ingestion)

Link to study